anonymous
Guest
anonymous
Guest
I agree. I’m just a Sales Specialist and don’t claim to be an “insider” but Novartis is a business. To be most profitable, they would just lift Xiidra and place with their existing sales force (already calling in same customers).
Normally I would agree, but they have made public statements of their intentions. Just as they did with a Retina products and hired Retina team. The current glaucoma reps have a full bag with more products coming. They spun off the contact lens business unit and are ready to expand.